Metabolic Disease

(-)-Epigallocatechin-4'-O-methylether ((-)-EGC-4'-O-ME) is an orally active natural phenolic catechin with antioxidant, free radical-scavenging and hepatoprotective activities. (-)-Epigallocatechin-4'-O-methylether interferes with radiation-induced free radical formation, scavenges DPPH free radicals, inhibits carbon tetrachloride-induced increases in serum GOT and GPT, suppresses carbon tetrachloride-induced TBA-RS formation, and counteracts carbon tetrachloride-induced hepatocyte toxicity. (-)-Epigallocatechin-4'-O-methylether binds specifically to human serum albumin. (-)-Epigallocatechin-4'-O-methylether can be used in studies related to liver injury.

Radish root extract (Raphanus sativus root extract) is an extract from radish (Raphanus sativus) that can be used in diabetes research.

6-Oxooctanoyl-CoA (6-Oxooctanoyl-coenzyme A) is a coenzyme A derivative.

Imidazole-5-propionic acid-¹³C₃ (Imidazolepropionic acid-¹³C₃) is the ¹³C-labeled Imidazole-5-propionic acid (HY-W045271). Imidazole-5-propionic acid (Imidazolepropionic acid) is a urinary metabolite of L-histidine (HY-N0832). Imidazole-5-propionic acid can be used in the research of intestinal diseases and cardiovascular diseases.

α-Glucosidase-IN-48 (compound 9) is a potent inhibitor of α-Glucosidase, with IC₅₀ of 1.30 μM.

GSK-3β inhibitor 7 is a GSK-3β inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder.

M 16209 is an orally active aldose reductase (AR) inhibitor. M 16209 inhibits partially purified AR from various sources with IC₅₀ values of 0.12, 0.24, 4.5, 1.2 and 9.3 μM for rat lens AR, bovine lens AR, bovine kidney AR, canine lens AR and human placental AR. M 16209 can be used for the research of metabolic disease, such as diabetes.

cis-9,10-Methylenehexadecanoyl-CoA (cis-9,10-Methylenehexadecanoyl-coenzyme A) is a coenzyme A derivative.

DRAK1/2-IN-2 (Compound Y17) is a DRAK1/2 inhibitor with IC₅₀ values for DRAK2 and DRAK1 of 353.2 nM and 507.4 nM respectively. DRAK1/2-IN-2 can enhance mitochondrial membrane potential and glucose-stimulated insulin secretion (GSIS). DRAK1/2-IN-2 resists lipotoxicity-induced cell apoptosis. DRAK1/2-IN-2 significantly inhibits the secretion of pro-inflammatory cytokine IL-1β, thereby exerting an anti-inflammatory effect. DRAK1/2-IN-2 can significantly lower the blood glucose levels of mice. DRAK1/2-IN-2 can be used in diabetes research.

Dersimelagon phosphate is an orally active, selective melanocortin 1 receptor (MC1R) agonist with EC₅₀ values of 8.16, 3.91, 1.14 and 0.251 nM for human (h), cynomolgus monkey (cm), mouse (m) and rat (r) MC1R, respectively. Dersimelagon phosphate shows good affinity for hMC1R and hMC4R with K_i values of 2.26, 32.9 nM, respectively. Dersimelagon phosphate can be used for the research of skin pigmentation.

BIM-23197 is a selective SST2 (IC₅₀ = 0.19 nM) agonist. BIM-23197 can effectively stimulate intracellular calcium mobilization in cells expressing SST2. BIM-23197 can be used for research on endocrine related conditions.

Ambroxol (NA-872) acefylline, an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol acefylline is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol acefylline induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research.

Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.

DPP-4-IN-12 (compound 46) is a potent DPP-4 inhibitor with IC₅₀ value of 2 nM. DPP-4-IN-12 can be used in the study of type 2 diabetes.

α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin (HY-13753)-induced diabetic rats. Antidiabetic activity.

AldoView precursor-1 (Compound 7) is the key labeling precursor for the synthetic radioactive PET tracer [¹⁸F] AldoView. [¹⁸F] AldoView is a selective aldosterone synthase PET tracer used for imaging in primary hyperaldosteronism.

GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

Canaline-CoA (Canaline-coenzyme A) is a coenzyme A derivative.

NIR-RED ATP Probe is a NIR-II fluorescent probe. NIR-RED ATP Probe exhibits high affinity and selectivity for ATP and can non-invasively and with high contrast detect changes in ATP concentration at the cellular level, with minimal interference to the abundant biomolecules within the cells. NIR-RED ATP Probe can be used as a biomarker detection tool for drug-induced liver injury (DILI).